Pateras I, Igea A, Nikas I, Leventakou D, Koufopoulos N, Ieronimaki A
    
    
    Int J Mol Sci. 2024; 25(2).
  
  
    PMID: 38279253
    
          PMC: 10816510.
    
          DOI: 10.3390/ijms25021251.
      
 
                                  
  
    Han Y, Wang J, Xu B
    
    
    J Pers Med. 2023; 13(3).
  
  
    PMID: 36983639
    
          PMC: 10054905.
    
          DOI: 10.3390/jpm13030457.
      
 
                                  
  
    Cassetta L, Pollard J
    
    
    Nat Rev Cancer. 2023; 23(4):238-257.
  
  
    PMID: 36792751
    
    
          DOI: 10.1038/s41568-022-00547-1.
      
 
                                  
  
    Luque M, Sanz-Alvarez M, Morales-Gallego M, Madoz-Gurpide J, Zazo S, Dominguez C
    
    
    Cancers (Basel). 2022; 14(24).
  
  
    PMID: 36551522
    
          PMC: 9776701.
    
          DOI: 10.3390/cancers14246034.
      
 
                                  
  
    Zhang J, Cai X, Cui W, Wei Z
    
    
    Genes (Basel). 2022; 13(10).
  
  
    PMID: 36292671
    
          PMC: 9601900.
    
          DOI: 10.3390/genes13101786.
      
 
                              
              
                              
                                      
  Prognostic Characteristics of Immune-Related Genes and the Related Regulatory Axis in Patients With Stage N+M0 Breast Cancer.
  
    Tian C, Wang Y, Song X
    
    
    Front Oncol. 2022; 12:878219.
  
  
    PMID: 35785160
    
          PMC: 9243266.
    
          DOI: 10.3389/fonc.2022.878219.
      
 
                                          
                                                          
  Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.
  
    Uchimiak K, Badowska-Kozakiewicz A, Sobiborowicz-Sadowska A, Deptala A
    
    
    Clin Med Insights Oncol. 2022; 16:11795549221099869.
  
  
    PMID: 35721387
    
          PMC: 9201309.
    
          DOI: 10.1177/11795549221099869.
      
 
                                          
                                                          
  Identification of the three subtypes and the prognostic characteristics of stomach adenocarcinoma: analysis of the hypoxia-related long non-coding RNAs.
  
    Fan Z, Wang Y, Niu R
    
    
    Funct Integr Genomics. 2022; 22(5):919-936.
  
  
    PMID: 35665866
    
    
          DOI: 10.1007/s10142-022-00867-3.
      
 
                                          
                                                          
  The next wave of cellular immunotherapies in pancreatic cancer.
  
    Yeo D, Giardina C, Saxena P, Rasko J
    
    
    Mol Ther Oncolytics. 2022; 24:561-576.
  
  
    PMID: 35229033
    
          PMC: 8857655.
    
          DOI: 10.1016/j.omto.2022.01.010.
      
 
                                          
                                                          
  Nomogram to Predict Tumor-Infiltrating Lymphocytes in Breast Cancer Patients.
  
    Feng J, Li J, Huang X, Yi J, Wu H, Zou X
    
    
    Front Mol Biosci. 2021; 8:761163.
  
  
    PMID: 34901155
    
          PMC: 8662984.
    
          DOI: 10.3389/fmolb.2021.761163.
      
 
                                          
                                                          
  Comparison of Tumor Infiltrating Lymphocyte Density with Histopathological Parameters and Effect on Prognosis in Head and Neck Squamous Cell Cancers.
  
    Sari E, Tokat T, Tarhan O, Dag H, Zeki Yilmaz Y, Yener H
    
    
    Sisli Etfal Hastan Tıp Bul. 2020; 54(4):438-443.
  
  
    PMID: 33364884
    
          PMC: 7751247.
    
          DOI: 10.14744/SEMB.2019.48208.
      
 
                                          
                                                          
  Identification and Validation of an Immunological Expression-Based Prognostic Signature in Breast Cancer.
  
    Pei J, Li Y, Su T, Zhang Q, He X, Tao D
    
    
    Front Genet. 2020; 11:912.
  
  
    PMID: 33193571
    
          PMC: 7526716.
    
          DOI: 10.3389/fgene.2020.00912.
      
 
                                          
                                                          
  Immunotherapeutic strategies in breast cancer: A clinical update.
  
    Zhang J, Plitas G
    
    
    J Surg Oncol. 2020; 123(3):710-717.
  
  
    PMID: 33155281
    
          PMC: 7889634.
    
          DOI: 10.1002/jso.26287.
      
 
                                          
                                                          
  Identification of prognosis-related genes in the tumor microenvironment of stomach adenocarcinoma by TCGA and GEO datasets.
  
    Ren N, Liang B, Li Y
    
    
    Biosci Rep. 2020; 40(10).
  
  
    PMID: 33015704
    
          PMC: 7560520.
    
          DOI: 10.1042/BSR20200980.
      
 
                                          
                                                          
  Carcinoma and Sarcoma Microenvironment at a Glance: Where We Are.
  
    Saggioro M, DAngelo E, Bisogno G, Agostini M, Pozzobon M
    
    
    Front Oncol. 2020; 10:76.
  
  
    PMID: 32195166
    
          PMC: 7063801.
    
          DOI: 10.3389/fonc.2020.00076.
      
 
                                          
                                                          
  Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study.
  
    Wang K, Li H, Xiong Y, Shi Y, Li Z, Li J
    
    
    Cancer Med. 2019; 8(2):686-700.
  
  
    PMID: 30677255
    
          PMC: 6382728.
    
          DOI: 10.1002/cam4.1880.
      
 
                                          
                                                          
  Attenuated Bacteria as Immunotherapeutic Tools for Cancer Treatment.
  
    Kaimala S, Al-Sbiei A, Cabral-Marques O, Fernandez-Cabezudo M, Al-Ramadi B
    
    
    Front Oncol. 2018; 8:136.
  
  
    PMID: 29765907
    
          PMC: 5938341.
    
          DOI: 10.3389/fonc.2018.00136.
      
 
                                          
                                                          
  The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis.
  
    Roufas C, Chasiotis D, Makris A, Efstathiades C, Dimopoulos C, Zaravinos A
    
    
    Front Oncol. 2018; 8:27.
  
  
    PMID: 29515971
    
          PMC: 5826382.
    
          DOI: 10.3389/fonc.2018.00027.
      
 
                                          
                                                          
  How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment.
  
    Saraiva D, Cabral M, Jacinto A, Braga S
    
    
    ESMO Open. 2017; 2(4):e000208.
  
  
    PMID: 29018573
    
          PMC: 5604720.
    
          DOI: 10.1136/esmoopen-2017-000208.
      
 
                                          
                                                          
  The colorectal cancer immune microenvironment and approach to immunotherapies.
  
    Koi M, Carethers J
    
    
    Future Oncol. 2017; 13(18):1633-1647.
  
  
    PMID: 28829193
    
          PMC: 6817965.
    
          DOI: 10.2217/fon-2017-0145.